



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

August 19, 2021

J.J. Finkelstein
President and Chief Executive Officer
REGENERX BIOPHARMACEUTICALS INC
15245 Shady Grove Road, Suite 470
Rockville, MD 20850

Re: REGENERX BIOPHARMACEUTICALS INC
Registration Statement on Form S-1
Filed August 16, 2021
File No. 333-258873

Dear Mr. Finkelstein:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Margaret Schwartz at 202-551-7153 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Kimberly Lowe, Esq.